Novitium Labs Profile
Key Indicators
- Authorised Capital ₹ 3.25 Cr
as on 11-12-2024
- Paid Up Capital ₹ 3.25 Cr
as on 11-12-2024
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
as on 11-12-2024
- Revenue 81.44%
(FY 2022)
- Profit 187.84%
(FY 2022)
- Ebitda 381.60%
(FY 2022)
- Net Worth 19.97%
(FY 2022)
- Total Assets 20.43%
(FY 2022)
About Novitium Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.25 Cr and a paid-up capital of Rs 3.25 Cr.
The company currently has active open charges totaling ₹0.50 M.
Shanmugam Muthusamy and Ayyavu Rajavel serve as directors at the Company.
- CIN/LLPIN
U74999TN2016PTC112516
- Company No.
112516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Novitium Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Muthusamy  | Director | 15-Sep-2016 | Current |
Ayyavu Rajavel  | Director | 15-Sep-2016 | Current |
Financial Performance of Novitium Labs.
Novitium Labs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 81.44% increase. The company also saw a substantial improvement in profitability, with a 187.84% increase in profit. The company's net worth Soared by an impressive increase of 19.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novitium Labs?
In 2022, Novitium Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saimirra Innopharm Private LimitedActive 24 years 10 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
Nuray Chemicals Private LimitedActive 12 years 7 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
Scitus Pharma Services Private LimitedActive 7 years 3 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
- Esjay Pharma Private LimitedActive 2 years 3 months
Shanmugam Muthusamy and Ayyavu Rajavel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Feb 2023 | ₹0.50 M | Open |
How Many Employees Work at Novitium Labs?
Novitium Labs has a workforce of 65 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novitium Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novitium Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
